DAWN — Day One Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.20bn
- $836.84m
- 23
- 18
- 78
- 34
Annual cashflow statement for Day One Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17 | -43.8 | -72.8 | -142 | -189 |
| Depreciation | |||||
| Non-Cash Items | 12 | 30.7 | 21.5 | 25.7 | 32.6 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.444 | -0.357 | 2.69 | 6.56 | 9.42 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -4.51 | -13.5 | -48.5 | -110 | -147 |
| Capital Expenditures | 0 | -0.092 | 0 | -0.026 | -0.224 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -8 | -255 | 129 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0 | -0.092 | -8 | -255 | 128 |
| Financing Cash Flow Items | 1 | 0 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 30.9 | 30 | 297 | 166 | 164 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 26.4 | 16.4 | 241 | -199 | 146 |